Skip to main content
. 2012 Jan 23;141(2 Suppl):e278S–e325S. doi: 10.1378/chest.11-2404

Table 25.

—[Section 2.5] Summary of Findings: IPCD Plus Anticoagulanta vs Anticoagulant for Major Orthopedic Surgeryb (Initial Prophylaxis Period Up to 14 Days)115,120

Outcomes No. of Participants (Studies) Quality of the Evidence (GRADE) Relative Effect (95% CI) Anticipated Absolute Effects
Risk With Anticoagulant Risk Difference With IPCD + Anticoagulant (95% CI)
Nonfatal PE
667 (4 studies)
Lowc,d due to risk of bias and imprecision
RR 0.96 (0.06-15)
3 per 1,000
0 fewer per 1,000 (from 3 fewer to 40 more)
Symptomatic DVT (as inferred from asymptomatic DVT)
2470 (5 studies)
Lowc,e due to risk of bias and indirectness
RR 0.26 (0.14-0.48)
Study population
50 per 1,000
Contemporary population (initial prophylaxis)f
8 per 1,000 6 fewer per 1,000 (from 4 fewer to 7 fewer)

See Table 1, 3, and 11 legends for expansion of abbreviations.

a

Anticoagulants used in both treatment and control groups: Borow et al,116 UFH or VKA; Bradley et al,117 UFH; Edwards et al,120 enoxaparin 30 mg bid; Eisele et al,118 certoparin 3,000 International Units/d; and Silbersack et al,119 enoxaparin 40 mg/d.

b

Borow et al116 included general surgery, orthopedics, gynecology, and vascular surgery patients; Bradley et al117 included THA; Edwards et al120 included THA and TKA patients; Eisele et al118 included total joint arthroplasty, knee surgery, tumor resection, open fixation of traumatic fractures, osteotomies, contusion injuries; and Silbersack120 included THA and TKA.

c

One study was quasi-randomized (Bradley et al117), and one study was classified as nonrandomized controlled clinical trial (Borow et al116). Randomization method was not clear in three trials (Edwards et al120; Eisele et al118; and Silbersack et al,119 which also did not provide enough information to judge allocation concealment). The personnel performing the DVT screening was not blinded in Eisele et al and likely not blinded in Edwards et al.

d

Only two events.

e

Mostly asymptomatic events.

f

Contemporary surgical population from which baseline risk of patient-important outcomes has been derived (contemporary era surgical technique, early mobilization, etc [see text for details on how baseline risks were calculated]).